Clinical trials: Overactive Bladder (OAB)
Overactive Bladder Syndrome, Urinary Incontinence, Urge
Effectiveness of Bilateral PTNS Compared to Unilateral PTNS for the Treatment of Overactive Bladder/Urge Incontinence
This study is designed to evaluate whether bilateral Posterior Tibial Nerve Stimulation is more effective than unilateral Posterior Tibial Nerve Stimulation at treating overactive bladder and urge urinary incontinence
- Trial name
- BUTTON (NCT03535857)
- Testing
- PTNS
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Gnankang Sarah Napoe
Treatment of Patients Suffering From Overactive Bladder (OAB)
BlueWind RENOVA iStim™ System for the Treatment of OAB
The OASIS study is prospective, interventional, multi-center study to evaluate the safety and efficacy of the BlueWind RENOVA iStim™ implantable tibial neuromodulation System for the treatment of patients diagnosed with…
- Trial name
- OASIS (NCT03596671)
- Testing
- RENOVA iStim™ System
- Where
- 23 sites in United States, Belgium and 2 more
- Volunteers
- 282 people
- Sponsor
- BlueWind Medical
Overactive Bladder
PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB
To evaluate the NURO system for the treatment of OAB in drug naïve patients.
- Trial name
- RESET (NCT02857816)
- Testing
- NURO System PTNM Therapy
- Where
- 11 sites in United States
- Volunteers
- 154 people
- Sponsor
- MedtronicNeuro
Lower Urinary Tract Symptoms, Overactive Bladder
Tetra-NIRS Clinical Study
The purpose of this evaluation is to validate the previous clinical study results using a Near-Infrared Spectroscopy (NIRS) device, as compared to the conventional urodynamics (UDS) testing.
- Trial name
- NCT00871975
- Testing
- Urodynamics + TETRA - NIRS
- Where
- 3 sites in United States, Canada and 1 more
- Volunteers
- 155 people
- Sponsor
- Laborie Medical Technologies Inc.
Overactive Bladder
A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)
The primary objective of the study was to investigate the efficacy of mirabegron versus placebo in male patients with OAB symptoms while taking the alpha blocker, tamsulosin, for BPH.
- Trial name
- NCT02656173
- Testing
- Mirabegron, Tamsulosin
- Where
- 58 sites in Japan, South Korea
- Volunteers
- 568 people
- Sponsor
- Astellas Pharma Inc
Overactive Bladder
The Efficacy of Solifenacin With or Without Tamsulosin in Adult Women With Overactive Bladder (OAB)
The aim of the study is to investigate if the combination therapy consisting of anticholinergics plus alpha-blockers could be beneficial for women suffering from Overactive Bladder (OAB).
- Trial name
- NCT01533597
- Testing
- Solifenacin, Solifenacin plus Tamsulosin
- Where
- South Korea
- Volunteers
- 70 people
- Sponsor
- Soonchunhyang University Hospital
Overactive Bladder, Urinary Urge Incontinence
Over Active Bladder Instillation Study - Botox
The purpose of this study is to determine whether women with overactive bladder (OAB) who receive direct instillation via a catheter of a Botulinum-A Toxin (Botox) with Dimethyl Sulfoxide (DMSO) solution experience significantly…
- Conditions
- Overactive Bladder, Urinary Urge Incontinence, Urinary Incontinence, Detrusor Hyperreflexia
- Trial name
- NCT00667095
- Testing
- Botox Instillation, DMSO Instillation
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Mayo Clinic
Urologic Diseases, Urinary Bladder Diseases
A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder
The purpose of this study is to examine how well two medicines in combination (solifenacin succinate and mirabegron) work in the treatment of bladder problems over a 12-week period.
- Conditions
- Urologic Diseases, Urinary Bladder Diseases, Urological Manifestations, Signs and Symptoms
- Trial name
- Symphony (NCT01340027)
- Testing
- Mirabegron, Solifenacin succinate
- Where
- 133 sites in Belarus, Belgium and 18 more
- Volunteers
- 1,307 people
- Sponsor
- Astellas Pharma Europe B.V.
Overactive Bladder (OAB)
A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)
The purpose of this study was to assess tolerability of mirabegron compared to tolterodine ER in the treatment of participants with symptoms of Overactive Bladder (OAB) as well as the impact of treatment on micturition frequency…
- Trial name
- PREFER (NCT02138747)
- Testing
- Mirabegron, Tolterodine ER
- Where
- 30 sites in United States, Canada
- Volunteers
- 376 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Overactive Bladder
Overactive Bladder Innovative Therapy Trial (OrBIT)
The purpose of this study is to compare percutaneous tibial nerve stimulation (PTNS) to drug therapy for the treatment of symptoms of overactive bladder (OAB).
- Trial name
- OrBIT (NCT00448175)
- Testing
- Urgent PC Neuromodulation System, Tolterodine
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Uroplasty, Inc
Overactive Bladder, Urge Incontinence
Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence
This trial is a prospective, multicenter, single-arm study of the safety and effectiveness of eCoinTM tibial nerve stimulation in subjects having overactive bladder (OAB) with urgency urinary incontinence (UUI).
- Conditions
- Overactive Bladder, Urge Incontinence, Incontinence, Urinary, Urinary Urge Incontinence
- Trial name
- NCT03556891
- Testing
- eCoin Tibial Nerve Stimulation
- Where
- 15 sites in United States
- Volunteers
- 133 people
- Sponsor
- Valencia Technologies Corporation
Overactive Bladder
Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia
This study will assess the long-term safety of vibegron when dosed up to 52 weeks in men with overactive bladder (OAB) symptoms on pharmacological therapy for Benign Prostatic Hyperplasia (BPH) who previously completed treatment…
- Trial name
- NCT04103450
- Testing
- Vibegron
- Where
- 35 sites in United States, Poland
- Volunteers
- 276 people
- Sponsor
- Urovant Sciences GmbH
Urinary Bladder, Overactive
Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
The study is intended to test efficacy, safety and tolerability of two doses of Mirabegron against placebo and compare the efficacy and safety with active comparator in patients with symptoms of overactive bladder.
- Trial name
- SCORPIO (NCT00689104)
- Testing
- Mirabegron, Tolterodine
- Where
- 218 sites in Australia, Austria and 28 more
- Volunteers
- 2,336 people
- Sponsor
- Astellas Pharma Inc
Multiple Sclerosis, Overactive Bladder
PTNS for Female Patients Suffering From Multiple Sclerosis
This is a pilot, single blind, randomized, sham-controlled trial to assess the benefit of Percutaneous Tibial Nerve Stimulation (PTNS) in treating bladder overactivity (OAB) symptoms in multiple sclerosis (MS) patients.
- Trial name
- PTNS-MS (NCT05422625)
- Testing
- PTNS Treatment
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Corewell Health East
Overactive Bladder
Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)
To evaluate the efficacy and safety of fesoterodine in comparison to tolterodine and placebo for overactive bladder
- Trial name
- NCT00444925
- Testing
- fesoterodine fumarate, tolterodine tartrate
- Where
- 178 sites in United States, Belgium and 27 more
- Volunteers
- 1,712 people
- Sponsor
- Pfizer
Overactive Bladder
Bacterial Genomic Sequencing in Overactive Bladder
No one really knows what causes overactive bladder syndrome (OAB). Urinary tract infection (UTI)causes similar symptoms to OAB with the difference being the presence of bacteria, as evidenced by routine microbiology cultures.
- Trial name
- NCT01642277
- Testing
- Solifenacin
- Where
- United States
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Loyola University
Benign Prostatic Hyperplasia, Overactive Bladder
A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
The purpose of the study was to assess the efficacy, safety, and tolerability of mirabegron versus placebo in men with overactive bladder (OAB) symptoms while taking tamsulosin hydrochloride for lower urinary tract symptoms…
- Trial name
- PLUS (NCT02757768)
- Testing
- Mirabegron, Tamsulosin Hydrochloride
- Where
- 79 sites in United States, Canada and 7 more
- Volunteers
- 715 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Urinary Bladder, Overactive
A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)
This is a 2-part study to assess if vibegron (MK-4618) reduces the number of daily urinations more effectively than placebo in participants with overactive bladder (OAB).
- Trial name
- NCT01314872
- Testing
- Vibegron, Tolterodine ER
- Volunteers
- 1,395 people
- Sponsor
- Merck Sharp & Dohme LLC
Overactive Bladder
A Trial of Transcutaneous Nerve Stimulation for OAB
Overactive bladder causes urinary frequency, urgency and in some cases urgency incontinence. This study is testing the efficacy of transcutaneous tibial nerve stimulation (using skin patch electrodes via a transcutaneous…
- Trial name
- NCT02511717
- Testing
- Transcutaneous tibial nerve stimulation
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Urge Incontinence, Overactive Bladder (OAB)
A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder
The purpose of this study was to evaluate the efficacy of mirabegron for the treatment of overactive bladder (OAB) in Chinese participants.
- Trial name
- NCT04562090
- Testing
- mirabegron
- Where
- 15 sites in China
- Volunteers
- 249 people
- Sponsor
- Astellas Pharma China, Inc.